Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

NASDAQ Market News June 4, 2021

NASDAQ Market News
Click here to email author

TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

Immunoassay Market Worth $46.5 Billion by 2028, Growing at a CAGR of 7.5% From 2021- Exclusive Report by Meticulous Research®

Ads